MIT team builds low-cost cancer urine test; Munich group creates MS test that works before symptoms appear;

> Engineers at MIT have come up with a low-cost urine test for cancer. Item

> Alberto Gutierrez, director of the FDA's Office of In Vitro Diagnostics in the Center for Devices and Radiological Health, will discuss the agency's guidance on in vitro diagnostic products for research use only or investigational use only during a Feb. 26 webinar hosted by the American Association for Clinical Chemistry. Item

> Researchers have found that combining Mutant-Allele Tumor Heterogeneity as a biomarker with a patient's HPV status can give an effective indicator of improved patient outcome in head and neck squamous cell carcinoma. Item

> Researchers at the Technical University of Munich came up with a blood test designed to help identify multiple sclerosis before any symptoms show up. Item

> A team of doctors and engineers is using computational modeling to build a quicker, less-expensive way to help spot prostate cancer. Story

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.